Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solvay Cleared From FDA Application Integrity Policy; Luvox Decision Pending

Executive Summary

Solvay has been cleared from FDA's Application Integrity Policy list as of April 9

You may also be interested in...



Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma

Solvay plans to continue working with Abbott on the Tricor franchise in the U.S. after acquiring Fournier Pharma

Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma

Solvay plans to continue working with Abbott on the Tricor franchise in the U.S. after acquiring Fournier Pharma

Solvay Estratest Female Sexual Dysfunction Studies Could Save Product – FDA

Solvay should provide studies supporting the use of Estratest (estrogen/methyltestosterone) for the treatment of female sexual dysfunction to keep the product on the market, FDA suggests

Related Content

UsernamePublicRestriction

Register

PS041631

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel